These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094 [TBL] [Abstract][Full Text] [Related]
26. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. De Stefano N; Stromillo ML; Giorgio A; Bartolozzi ML; Battaglini M; Baldini M; Portaccio E; Amato MP; Sormani MP J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):93-9. PubMed ID: 25904813 [TBL] [Abstract][Full Text] [Related]
27. Improving the SIENA performance using BEaST brain extraction. Nakamura K; Eskildsen SF; Narayanan S; Arnold DL; Collins DL; PLoS One; 2018; 13(9):e0196945. PubMed ID: 30235215 [TBL] [Abstract][Full Text] [Related]
28. Improving brain atrophy quantification with deep learning from automated labels using tissue similarity priors. Clèrigues A; Valverde S; Oliver A; Lladó X; Comput Biol Med; 2024 Sep; 179():108811. PubMed ID: 38991315 [TBL] [Abstract][Full Text] [Related]
29. Lifespan normative data on rates of brain volume changes. Battaglini M; Gentile G; Luchetti L; Giorgio A; Vrenken H; Barkhof F; Cover KS; Bakshi R; Chu R; Sormani MP; Enzinger C; Ropele S; Ciccarelli O; Wheeler-Kingshott C; Yiannakas M; Filippi M; Rocca MA; Preziosa P; Gallo A; Bisecco A; Palace J; Kong Y; Horakova D; Vaneckova M; Gasperini C; Ruggieri S; De Stefano N; Neurobiol Aging; 2019 Sep; 81():30-37. PubMed ID: 31207467 [TBL] [Abstract][Full Text] [Related]
30. Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. Zhou X; Sakaie KE; Debbins JP; Narayanan S; Fox RJ; Lowe MJ Magn Reson Imaging; 2018 Nov; 53():105-111. PubMed ID: 30048675 [TBL] [Abstract][Full Text] [Related]
32. Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration? Beadnall HN; Wang C; Van Hecke W; Ribbens A; Billiet T; Barnett MH Ther Adv Neurol Disord; 2019; 12():1756286418823462. PubMed ID: 30719080 [TBL] [Abstract][Full Text] [Related]
33. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987 [TBL] [Abstract][Full Text] [Related]
34. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Magraner M; Coret F; Casanova B Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507 [TBL] [Abstract][Full Text] [Related]
35. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101 [TBL] [Abstract][Full Text] [Related]
36. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034 [TBL] [Abstract][Full Text] [Related]
37. Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. Neacsu V; Jasperse B; Korteweg T; Knol DL; Valsasina P; Filippi M; Barkhof F; Rovaris M; Vrenken H; J Magn Reson Imaging; 2008 Sep; 28(3):559-65. PubMed ID: 18777529 [TBL] [Abstract][Full Text] [Related]
38. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. Mak E; Su L; Williams GB; Watson R; Firbank M; Blamire AM; O'Brien JT Neuroimage Clin; 2015; 7():456-62. PubMed ID: 25685712 [TBL] [Abstract][Full Text] [Related]
39. Reliability of brain atrophy measurements in multiple sclerosis using MRI: an assessment of six freely available software packages for cross-sectional analyses. van Nederpelt DR; Amiri H; Brouwer I; Noteboom S; Mokkink LB; Barkhof F; Vrenken H; Kuijer JPA Neuroradiology; 2023 Oct; 65(10):1459-1472. PubMed ID: 37526657 [TBL] [Abstract][Full Text] [Related]
40. The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study. Gentile G; Mattiesing RM; Brouwer I; van Schijndel RA; Uitdehaag BMJ; Twisk JWR; Kappos L; Freedman MS; Comi G; Jack D; Barkhof F; De Stefano N; Vrenken H; Battaglini M Neuroimage Clin; 2023; 38():103397. PubMed ID: 37086648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]